Johnson & Johnson invests 580 million euros, of which 125 will be allocated to the Latina plant and will support an increase in production capacity and build skills for the future. These are the impressive sums that Johnson & Johnson Innovative Medicine will invest in Italy over the next five years, demonstrating its renewed commitment to the country. An announcement that is part of a strategic plan that foresees an increase in investments of 9.2% every year in the period 2019-2023, three times higher than the average for the pharmaceutical sector, according to a new study by The European House – Ambrosetti. All this has translated into a 15% increase in employment in Italy over the last five years, reaching approximately 1,400 employees across the country.
“The Latina site, which represents an important part of Johnson & Johnson’s global supply chain – explains the pharmaceutical company – produces more than four billion tablets a year, for approximately 30 different products, and 97% of the production is exported, reaching patients all over the world. The investment plan will allow an increase in production capacity by more than 25%, as it will include innovative projects to support products under development and new production technologies, such as the Flex Line , to more efficiently manage the packaging of small production batches and a new continuous production line that will reduce the total end-to-end production time and allow medicines to reach patients more quickly.” “The Johnson & Johnson facility in Latina, Italy, is experiencing a significant evolution,” said Jorge Lopez, general manager of the Johnson & Johnson facility in Latina, “as we enhance our capabilities to serve more patients with innovative products. Has been recognized as a 4IR (Industry 4.0) site by the World Economic Forum thanks to our commitment to innovation and sustainability. This is a truly exciting time for our site focus on safety, quality and reliability as we work to deliver medicines to patients around the world every day.”
“Johnson & Johnson – added Oladapo Ajayi, vice president, Innovative Medicine Supply Chain of Johnson & Johnson – has a significant manufacturing presence throughout Europe and the Latina site is an important part of our global network. We continue to make important investments in our Supply Chain to support the growth of our current portfolio of medicines and our pipeline of innovative solutions, which will allow us to continue to provide products to the millions of patients around the world who rely on us every day.”
“Today’s event – commented the Minister of Business and Made in Italy, Adolfo Urso – shows us how the pharmaceutical sector has become a new growth model for Made in Italy, thanks to the impressive investments in research and innovation. This growth, 60% driven by foreign companies, allows the local production fabric involved in the supply chain to grow equally and favors its internationalisation”. “It is – the government representative specified – a sector that can give great satisfactions for opening Italy to the world and bringing the world to Italy. Italy, following the European elections, has become the most reliable country at a European level capable of attracting more and more foreign investments.” “The pharmaceutical hub of Lazio has a crucial role. It is a sector that focuses on quality – said the president of the Lazio Region Francesco Rocca – as demonstrated by the level of personnel employed and the large investment in the research and development sectors. The objective for the future remains to further strengthen the pharmaceutical and biomedical sector and launch the Rome Technopole as a structural project, also thanks to the resources coming from the Pnrr, thus giving new life to the industrial sector and at the same time building concrete responses to the health needs of people in diagnostic and therapeutic fields”.
